These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 18180917

  • 21. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V, Delrue L, Kelles A, Van Damme N, Van Huysse J, Berrevoet F, De Vos M, Duyck P, Peeters M.
    Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
    [Abstract] [Full Text] [Related]

  • 22. Performance of (18)F-FDG PET/CT as a postoperative surveillance imaging modality for asymptomatic advanced gastric cancer patients.
    Lee DY, Lee CH, Seo MJ, Lee SH, Ryu JS, Lee JJ.
    Ann Nucl Med; 2014 Oct; 28(8):789-95. PubMed ID: 24965850
    [Abstract] [Full Text] [Related]

  • 23. Comparison of FDG PET/CT and MRI in lymph node staging of endometrial cancer.
    Kim HJ, Cho A, Yun M, Kim YT, Kang WJ.
    Ann Nucl Med; 2016 Feb; 30(2):104-13. PubMed ID: 26546334
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed?
    Schaefer NG, Taverna C, Strobel K, Wastl C, Kurrer M, Hany TF.
    Radiology; 2007 Jul; 244(1):257-62. PubMed ID: 17581905
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent uterine cancer: comparison with PET and enhanced CT.
    Kitajima K, Murakami K, Yamasaki E, Domeki Y, Kaji Y, Morita S, Suganuma N, Sugimura K.
    Eur J Nucl Med Mol Imaging; 2009 Mar; 36(3):362-72. PubMed ID: 18931841
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Diagnostic value of (18)F-FDG PET/CT as first choice in the detection of recurrent colorectal cancer due to rising CEA.
    Gade M, Kubik M, Fisker RV, Thorlacius-Ussing O, Petersen LJ.
    Cancer Imaging; 2015 Aug 13; 15(1):11. PubMed ID: 26263901
    [Abstract] [Full Text] [Related]

  • 31. Clinical value of FDG PET/CT in the diagnosis of suspected recurrent ovarian cancer: is there an impact of FDG PET/CT on patient management?
    Bilici A, Ustaalioglu BB, Seker M, Canpolat N, Tekinsoy B, Salepci T, Gumus M.
    Eur J Nucl Med Mol Imaging; 2010 Jul 13; 37(7):1259-69. PubMed ID: 20309683
    [Abstract] [Full Text] [Related]

  • 32. Metabolic Tumor Volume on 18F-FDG PET/CT Improves Preoperative Identification of High-Risk Endometrial Carcinoma Patients.
    Husby JA, Reitan BC, Biermann M, Trovik J, Bjørge L, Magnussen IJ, Salvesen ØO, Salvesen HB, Haldorsen IS.
    J Nucl Med; 2015 Aug 13; 56(8):1191-8. PubMed ID: 26045311
    [Abstract] [Full Text] [Related]

  • 33. Performance of FDG-PET/CT in the diagnosis of recurrent endometrial cancer.
    Kitajima K, Murakami K, Yamasaki E, Hagiwara S, Fukasawa I, Inaba N, Kaji Y, Sugimura K.
    Ann Nucl Med; 2008 Feb 13; 22(2):103-9. PubMed ID: 18311534
    [Abstract] [Full Text] [Related]

  • 34. Clinical and prognostic value of 18F-FDG PET/CT in recurrent endometrial carcinoma.
    Albano D, Zizioli V, Odicino F, Giubbini R, Bertagna F.
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019 Feb 13; 38(2):87-93. PubMed ID: 30573388
    [Abstract] [Full Text] [Related]

  • 35. Effect of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography-guided management of suspected recurrent papillary thyroid carcinoma: long-term follow-up with tumour marker responses.
    Dennis K, Hay JH, Wilson DC.
    Clin Oncol (R Coll Radiol); 2012 Dec 13; 24(10):e168-72. PubMed ID: 22944464
    [Abstract] [Full Text] [Related]

  • 36. Integrated PET/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer.
    Mangili G, Picchio M, Sironi S, Viganò R, Rabaiotti E, Bornaghi D, Bettinardi V, Crivellaro C, Messa C, Fazio F.
    Eur J Nucl Med Mol Imaging; 2007 May 13; 34(5):658-666. PubMed ID: 17180659
    [Abstract] [Full Text] [Related]

  • 37. Clinical value of FDG-PET in the follow up of post-operative patients with endometrial cancer.
    Saga T, Higashi T, Ishimori T, Mamede M, Nakamoto Y, Mukai T, Fujita T, Togashi K, Yura S, Higuchi T, Kita M, Fujii S, Konishi J.
    Ann Nucl Med; 2003 May 13; 17(3):197-203. PubMed ID: 12846541
    [Abstract] [Full Text] [Related]

  • 38. The utility of 18 F-FDG PET/CT for suspected recurrent breast cancer: impact and prognostic stratification.
    Cochet A, David S, Moodie K, Drummond E, Dutu G, MacManus M, Chua B, Hicks RJ.
    Cancer Imaging; 2014 Apr 22; 14(1):13. PubMed ID: 25608599
    [Abstract] [Full Text] [Related]

  • 39. A treatment selection protocol for recurrent ovarian cancer patients: the role of FDG-PET/CT and staging laparoscopy.
    Fagotti A, Fanfani F, Rossitto C, Lorusso D, De Gaetano AM, Giordano A, Vizzielli G, Scambia G.
    Oncology; 2008 Apr 22; 75(3-4):152-8. PubMed ID: 18827492
    [Abstract] [Full Text] [Related]

  • 40. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP, Komar G, Seppänen MP, Dean KI, Minn HR, Kajander SA, Rinta-Kiikka I, Alanen K, Borra RJ, Puolakkainen PA, Nuutila P, Ovaska JT.
    Ann Surg; 2009 Dec 22; 250(6):957-63. PubMed ID: 19687736
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.